|
|
[Report]
hERG SCREENING - A MARKET INSIGHT REPORT
Published: 2008/01
|
|
 |
|
|
|
Table of Contents
I. SCOPE AND METHODOLOGY
II. REPORT SYNOPSIS
- 1. Introduction
- hERG Screening
- Normal Functioning of Heart
- About the Heart
- Electrocardiogram (EKG or ECG)
- 2.Global Market Analysis
- Exhibit 1: hERG Screening (2005-2012) - Global Market Analysis (Current
& Future) in US$ Million (Graphical Representation Included)
- Exhibit 2: List of Major Global Companies
- 3. Regional Market Analysis
- North America
- Exhibit 3: hERG Screening (2005-2012) - North American Market Analysis
(Current & Future) in US$ Million(Graphical Representation Included)
- Major Companies in North America
- ABR-Affinity BioReagents, Inc. (USA)
- Aurora Biomed, Inc. (Canada)
- AutoMate Scientific, Inc. (USA)
- AVIVA Biosciences Corporation (USA)
- Caliper Life Sciences, Inc.(USA)
- Cellular Dynamics International (USA)
- ChanTest Corporation (USA)
- Charles River Laboratories, Inc. (USA)
- CorDynamics (USA)
- Covance, Inc. (USA)
- Invitrogen, Inc. (USA)
- Lifespan Biosciences, Inc. (USA)
- MDS, Inc (Canada)
- Millipore Corporation (USA)
- Molecular Devices Corporation (USA)
- Neurion Pharmaceuticals, Inc. (USA)
- Novascreen Biosciences Corporation (USA)
- Novus Biologicals, Inc. (USA)
- Santa Cruz Biotechnology, Inc. (USA)
- Schrodinger, LLC (USA)
- Sigma-Aldrich Corporation (USA)
- Tocris Bioscience (USA)
- Wisconsin Alumni Research Foundation (WARF) (USA)
- Europe
- Exhibit 4: hERG Screening (2005-2012) - European Analysis (Current &
Future) in US$ Million (Graphical Representation Included)
- Major Companies in Europe
- Abcam PLC (UK)
- Astrazeneca PLC (UK)
- Aureus Pharma (France)
- bSys GmbH (Switzerland)
- Cambridge BioScience Ltd (UK)
- Cerep SA (France)
- ChemAxon Kft. (Hungary)
- CreaCell (France)
- Cyprotex plc (UK)
- Cytocentrics AG (Germany)
- Flyion GmbH (Germany)
- Nanion Technologies GmbH (Germany)
- Neurosolutions Ltd. (UK)
- RCC Ltd. (Switzerland)
- Sophion Bioscience A/S (Denmark)
- Asia-Pacific
- Exhibit 5: hERG Screening (2005-2012) -Asia-Pacific Market Analysis
(Current & Future) in US$ Million(Graphical Representation Included)
- Major Companies in Asia-Pacific
- Abnova Corp. (Taiwan)
- RDDT (Australia)
- Strand Life Sciences (India)
- Synergia Life sciences (India)
- Tetra Q (Australia)
- WuXi PharmaTech Co.Ltd (China)
- Rest of World
- Exhibit 6: hERG Screening (2005-2012) - Rest of World* Market Analysis
(Current & Future) in US$ Million(Graphical Representation Included)
- More About the Patch Clamp Technique
- Short QT Syndome
- Long QT syndrome
- Signs and symptoms
- Causes
- QT interval
- Types of LQTS
- Genetical LQTS
- Acquired LQTS
- The Long QT syndrome and Torsade de pointes
- Recording the Electrical Activity of Heart Beat
- Diagnosis of LQTS
- Treatment
- Cell Lines
- Qualified Cell Lines for Cell-Based ADME and Toxicity Evaluation
III. PRODUCT/TECHNOLOGY RESEARCH
- 1. Introduction
- hERG Screening Growth Trends - Global Markets
- Exhibit 7: Global* Market for hERG Screening: Geographic Regions
(Asia-Pacific, Europe, Canada, Japan and United States) Ranked by
Projected CAGR for 2005 through 2012 (Graphical Representaton Included)
- Ion Channels
- History
- Basic Features of Ion Channel
- Biological Role
- The Patch Clamp Technique
- Methodology
- Technique Configurations
- The On-cell
- The Inside out
- The Whole-cell
- The Outside out
- The Perforated whole-cell
- The Patch Clamp Technique Application
- QPatch 16
- QPatch HT
- Exhibit 8: List of Companies Developing Patch clamp
- Q Patch Applications
- QPATCH HT: Effective Application in Ion Channel Drug Discovery
- Screening Station
- Plates
- Cell Preparation Unit
- Liquid Handling System
- Touch Screen
- About Q Plate
- The Q Plate Technique
- Q Plate Prospects
- Data Acquisition
- Q Patch software
- Exhibit 9: Companies Developing hERG Soft Ware
- Types of Ion Channels
- Voltage-gated Ion Channel
- Ligand-gated Ion Channel
- Introduction
- Regulation
- Clinical Relevance
- Diversity of Ion Channels
- Potassium Channels
- Voltage-gated Potassium Channels
- Diseases Related to Ion Channels
- Exhibit 10: Diseases Related to Ion Channel Function
- Ion Channel Genes of the Human Genome
- Ion Channels as Drug Targets
- Technologies for Ion Channel Characterization
- Cell Lines
- Exhibit 11: Companies Developing Cell lines for hERG Screening
- Application of HEK 293 Cells
- CHO or Chinese Hamster Ovary Cells
- Transfection
- Calcium Phosphate Transfection
- Normal Cardiac Cycle
- Definition
- Role of Potassium, Magnesium and Calcium in Normal Functioning of Heart
- Magnesium
- Calcium
- Potassium
- Membrane Potential
- Improper Membrane Potential
- Description
- Task in Human Well being
- Common Abnormalities and Ailments
- Atrial Arrhythmias
- Ventricular Arrhythmias
- Cardiac Phase
- Blood Pressure
- Electrocardiogram (EKG or ECG):
- History
- QRS Complex:
- T wave
- Abnormality in Potassium Ion Channel:
- Short QT Syndrome
- Arrhythmia:
- Torsades de Pointes : a cardiac arrhythmia
- Characteristics of TdP
- Causes of TdP
- Risk factors for TdP
- Treatment
- QT Interval
- Long QT Syndrome
- LQTS - The Causes
- LQTS - Risks
- LQTS - Signs and Symptoms
- Screening and Diagnostic Procedures
- Complications
- LQTS - Treatment
- Medical Devices and Surgical Procedures
- Clinical Trials
- LQTS - The Types
- Inherited Long QT syndrome
- Exhibit 12: Drugs to be Avoided by Congenital QT Patients
- Exhibit 13: Drugs (Withdrawn From Market) Avoided by Congenital QT
Patients
- Genetic Basis and Treatment
- Genetic Basis of LQTS
- LQTS Associated Syndromes
- Exhibit 14: Drugs Which Block the hERG Channel.
- Cofactors of Drug Induced LQTS:
- Symptoms for Identification of Drug Induced LQTS
- High probability of Drug Induced LQTS
- Suspected Cases of Drug Induced LQTS
- Unlikely Case of Drug Induced LQTS
- Functioning of Heart
- Drug Discovery Concerns
- Action from Drug Approving Authorities
- Exhibit 15: Drugs (Discontinued in the Market) which Block the hERG
Channel.
- Role of hERG Blockers in Cardiac Disorders
- The characteristics and Clinical Applications of Cardiac hERG/I (Kr)
Potassium Channel
- Cibenzoline an effective Na+-channel blocker
- Biophysical Properties and Molecular Determinants of ziprasidone and
its Role in Block Opening hERG
- In silico Modeling in hERG Channel Blockers
- hERG Channel Archetypes and Pharmacophores
- In silico Model Improvement and Assessment of HERG Binding
- Testing In Silico for hERG K+ Channel Blockers
- In Silico Categorization of hERG Channel Blockers: a Skill-Based Strategy
- hERG Screening - Drugs Banned
- Exhibit 16: List of Banned Drugs for Inducing LQTS
- 2. Product Trends
- The GLP hERG Channel Assay
- Benefits Attributed to the Use of CDI Services
- ICR 8000 - The latest Entrant in the Ion Channel Technology
- Applications of ICR 800
- Features and Parameters of ICR 800
- Features and Parameters of ICR 12000
- Exhibit 17: Companies Offering hERG Screening Services
- Rubidium Flux Assay
- IonWorks® HT in hERG Channel Screening
- Measurement of hERG Channel Currents Using IonWorks HT System
- Sophion' s Q Patch
- QPatch 16
- QPatch HT
- Cell Lines in hERG Screening:
IV. MARKET DYNAMICS
- 1. Market Overview
- Global Market Analysis
- Exhibit 18: hERG Screening (2005-2012) - Global Market Analysis
(Current & Future) by Geographic Region for North America, Europe,
Asia-Pacific and Rest of World in US$ Million (Graphical Representation
Included)
- Exhibit 19: hERG Screening (2006, 2009, 2012) Percentage Breakdown of
Global Market value by Geographic Region for North America, Europe,
Asia-Pacific and Rest of World (Graphical Representation Included)
- 2. Major Companies in hERG Screening Industry
- Abcam PLC (UK)
- Abnova Corp. (Taiwan)
- ABR-Affinity BioReagents, Inc. (USA)
- Astrazeneca PLC (UK)
- Aureus Pharma (France)
- Aurora Biomed, Inc. (Canada)
- AutoMate Scientific, Inc. (USA)
- AVIVA Biosciences Corporation (USA)
- bSys GmbH (Switzerland)
- Caliper Life Sciences, Inc. (USA)
- Cambridge BioScience Ltd (UK)
- Cellular Dynamics International (USA)
- Cerep SA (France)
- ChanTest Corporation (USA)
- Charles River Laboratories, Inc. (USA)
- ChemAxon Kft. (Hungary)
- CorDynamics (USA)
- Covance, Inc. (USA)
- CreaCell (France)
- Cyprotex plc (UK)
- Cytocentrics AG (Germany)
- Flyion GmbH (Germany)
- Invitrogen, Inc. (USA)
- Lifespan Biosciences, Inc. (USA)
- MDS, Inc (Canada)
- Millipore Corporation (USA)
- Molecular Devices Corporation (USA)
- Nanion Technologies GmbH (Germany)
- Neurion Pharmaceuticals, Inc. (USA)
- Neurosolutions Ltd. (UK)
- Novascreen Biosciences Corporation (USA)
- Novus Biologicals, Inc. (USA)
- RCC Ltd. (Switzerland)
- RDDT (Australia)
- Santa Cruz Biotechnology, Inc. (USA)
- Schrodinger, LLC (USA)
- Sigma-Aldrich Corporation (USA)
- Sophion Bioscience A/S (Denmark)
- Strand Life Sciences (India)
- Synergia Life sciences (India)
- Tetra Q (Australia)
- Tocris Bioscience (USA)
- Wisconsin Alumni Research Foundation (WARF) (USA)
- WuXi PharmaTech Co.Ltd (China)
- 3. Major Activities in hERG Screening Industry
- Novel Cardiac Model Developed by PhysioStim to Investigate Compound
Assays
- Neuromed Licenses AurSCOPE Ion Channel Database from Aureus Pharma
- PhysioStim Deploys the Innovative Cardiac Pharmacological System
- TetraQ to Market NeuroSolutions' Products in Australasia
- Charles River Laboratories to Start a New Pre-Clinical Services Facility
in Quebec
- Charles River Laboratories Completes Joint Venture with Shanghai
BioExplorer
- Aureus Pharma Forms Alliance with MDL® Isentris®
- Millipore Provides First L-type Calcium Channel for Drug Testing
- Aureus Pharma Grants License to Bayer CropScience for its AurSCOPE
Knowledge Databases Cerep Extends Pharmaco-Informatics Alliance with Pfizer
- Cerep Renews Agreement for 2007 with Eli Lilly
- Covance Acquires Orbitrap™ to Become the First CRO with Latest
Mass Spectrometer Technology
- AVIVA Biosciences Signs Distribution Agreement with Cosmo Bio Making
Available its Electrophysiology Service in Japan
- Covance Granted License for B-CLEAR® to Predict In-vivo Liver
Disposition from In-vitro Assessments
- Joint Venture Between Strand and BioIT Alliance
- Sophion Bioscience Introduces New Revolutionary QPatch HT
- Origenis Becomes First Customer to Aureus Pharma' s AurWEB
- Aureus Pharma Signs License Agreement with Xention for AurSCOPE Ion
Channel Knowledge Database
- Aureus Pharma Licenses Three Knowledge Databases to Siena Biotech S.p.A.
- Joint Venture between TetraQ and VivoPharma for New Pre-Clinical Drug
Development Services
- Serologicals Corporation Acquires Cytomyx
- Aureus Pharma Launches AurWEB™ - The New Web Portal Solution for
Knowledge Driven Drug Discovery
- Strand and Pharmidex to Jointly Develop New Silico Technology for CNS
Drug Discovery
- GlaxoSmithKline Granted License to Use Aureus Pharma' s Knowledge
Databases
- Strand Signs Agreement with ChemAxon to Develop New Software
- Sophion Bioscience Initiates Joint Venture with Merck on QPatch HT
- Sophion Enters Japanese Market
- Bio-Rad Forms a Joint Venture with Aureus Pharma and Equbits LLC for In
Silico Prediction of Biological Properties in Preclinical Drug Research
- Aureus Pharma Extends Alliance with Sanofi-Aventis
- Cyprotex Introduces New Innovative Screening Service
- Sophion and Hydra Form One-of-a-Kind Reference Site for QPatch Automated
Patch Clamp System
- Aureus Pharma Launches AurSCOPE® hERG Channel - The New Cardio
- toxicity Related Database
- Molecular Devices Launches New IonWorks® Quattro™ System for
Accelerated Ion Channel Screening
- 4. Regional Market Analysis
- A. North America
- Market Analysis
- Exhibit 20: hERG Screening(2005-2012) - North American Market
Analysis (Current & Future) in US$ Million (Graphical Representation
Included)
- Exhibit 21: List of Major Companies in North America
- Analysis by Geographic Region
- Exhibit 22: hERG Screening (2005-2012) - North American Market
Analysis (Current & Future) by Geographic Region for United States and
Canada in US$ Million (Graphical Representation Included)
- Exhibit 23: hERG Screening (2006, 2009, 2012) Percentage Breakdown
of North American Market Value by Geographic Regions for United States
and Canada (Graphical Representation Included)
- B. Europe
- Market Analysis
- Exhibit 24: hERG Screening (2005-2012) - European Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Exhibit 25: List of Major Companies in Europe
- Analysis by Geographic Region
- Exhibit 26: hERG Screening (2005-2012) - European Market Analysis
(Current & Future) by Geographic Region for United Kingdom, Germany,
France, Switzerland, and Rest of Europe in US$ Million (Graphical
Representation Included)
- Exhibit 27: hERG Screening (2006, 2009, 2012) Percentage Breakdown
of Europe Market Value by Geographic Regions for United Kingdom Germany,
France, Switzerland and Rest of Europe(Graphical Representation Included)
- C. Asia-Pacific
- Market Analysis
- Exhibit 28: hERG Screening (2005-2012) - Asia-Pacific Market
Analysis (Current & Future) in US$ Million (Graphical Representation
Included)
- Exhibit 29: List of Major Companies in Asia-Pacific
- Analysis by Geographic Region
- Exhibit 30: hERG Screening (2005-2012) - Asia-Pacific Market
Analysis (Current & Future) by Geographic Region for Australia, China,
India, and Rest of Asia-Pacific in US$ Million (Graphical Representation
Included)
- Exhibit 31: hERG Screening (2006, 2009, 2012) Percentage Breakdown
of Asia-Pacific Market Value by Geographic Regions for Australia, China,
India and Rest of Asia-pacific (Graphical Representation Included)
- D. Rest of World
- Market Analysis
- Exhibit 32: hERG Screening (2005-2012) - Rest of World Market
Analysis (Current & Future) in US$ Million (Graphical Representation
Included)
- 5. hERG Screening -The Industry Out Look
V. CORPORATE DIRECTORY
|
|
|
|
|
|
|
[Report]
hERG SCREENING - A MARKET INSIGHT REPORT
Published: 2008/01
|
Published by : RI Technologies  |
|
|
Price:
|
Product Code : RIT63054 |
|
|
Please inform me when related publications are released
|
|
|
View Cart
